Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Gains from Investment Securities: 2019-2023

Historic Gains from Investment Securities for Avidity Biosciences (RNA) over the last 4 years, with Dec 2023 value amounting to $1.7 million.

  • Avidity Biosciences' Gains from Investment Securities rose 4537.69% to $12.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was $13.2 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2023, which is N/A change from last year.
  • Latest data reveals that Avidity Biosciences reported Gains from Investment Securities of $1.7 million as of FY2023, which was down 69.87% from $5.8 million recorded in FY2021.
  • In the past 5 years, Avidity Biosciences' Gains from Investment Securities ranged from a high of $5.8 million in FY2021 and a low of $1.7 million during FY2019.
  • Moreover, its 2-year median value for Gains from Investment Securities was $3.8 million (2021), whereas its average is $3.8 million.
  • Data for Avidity Biosciences' Gains from Investment Securities shows a peak YoY spiked of 127.23% (in 2020) over the last 5 years.
  • Over the past 4 years, Avidity Biosciences' Gains from Investment Securities (Yearly) stood at $1.7 million in 2019, then spiked by 127.23% to $3.8 million in 2020, then soared by 52.53% to $5.8 million in 2021, then reached $1.7 million in 2023.